InvestorsHub Logo
Followers 319
Posts 15832
Boards Moderated 0
Alias Born 01/02/2010

Re: None

Thursday, 11/02/2017 8:29:08 AM

Thursday, November 02, 2017 8:29:08 AM

Post# of 8422
From CC last night.

" I can't really go into more detail other than that until we have additional meetings and really flesh out what the protocol will look like, we intend to communicate that to the street as soon as we have a definitive plan in place just like we did with the Phase 2b/3 adaptive study design that we have with SYN-010.

Katherine Xu

So can you describe the interest level from industry, potential partners on this program?

Jeff Riley

Like I told you last quarter, we're talking to everybody Katherine at this point in time. I mean, there are discussions on for both drugs, from disparate companies. There's only a couple that are looking at both drugs together. The industry I think is beginning to look at licensing again. I think it's been pretty dry for the last two or three years from late stage Phase 2, Phase 3, the classic licensing deals. I think it's beginning to improve. Ken Frazier at Merck actually signaled that the other day that they were going to begin looking for things at Merck and I would guess that Pfizer said something similar as well in their earnings call. So I believe that the tide is going to turn for the big guys to start acquiring assets and filling their pipeline. So again, the only guidance I can give you is when we have a deal in hand and it becomes relevant, we'll announce it."

https://seekingalpha.com/article/4119328-synthetic-biologics-syn-ceo-jeff-riley-q3-2017-results-earnings-call-transcript?page=1

"Keith Markey

Couple of questions. I was just wondering if you might explain to us what you mean by -- what you're doing to solidify the clinical infrastructure for SYN-010. What does that involve?

Jeff Riley

It’s Jeff. Essentially, we’ve signaled the street that we're not going to spend the money to do that program ourselves at this time. It's just not something that we can do. We don't want to take the dilution in raising capital nor do we want to do that. So we're looking at building the infrastructure. We have great CROs over in Europe as well as here in the United States. We've talked to several. I think we have our prime lead CROs for both Europe as well as the United States and we're ready to go. So again, discussions on the business development side are, it’s highly likely that if we did get a deal, we will be the ones actually doing the work in collaboration with a CRO.

So that's what we meant by solidifying the clinical development plan. We're also beginning to obviously pivot toward more of a commercialization perspective as a company, because we're getting close to the end of this long road, 25th mile and a marathon if you will. So we are beginning to look at some of the commercialization components, the markets, how we would position the drug and we do have a head of marketing that is looking at all of these things at this point in time as well as manufacturing of both of the drugs. The manufacturing for SYN-010 is fairly bullet proof. I think we're ready to rock and roll and there is still some work to be done on ribaxamase to make sure that we have cGMP and CMC up and running for that biologic."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TOVX News